Popular Articles

Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties Of TAK-652 For The Treatment Of HIV
Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV. These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing. Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations. "These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.
generic viagra online
Also In Global Health News: Uganda ARVs; Malaria In Yemen; Seasonal Hunger; Zimbabwe Maternal Deaths; Nigeria Polio Campaign
Lack Of Funds Prevents HIV-Positive People In Uganda From Receiving Antiretroviral Treatment
News of the day
Genetic And Chromosomal Abnormalities In Embryos Detected By New Test
One-step screening for both genetic and chromosomal abnormalities has come a stage closer as scientists announced that an embryo test they have been developing has successfully screened cells taken from spare embryos that were known to have cystic fibrosis.
Mental Health

Good Bet In Market Pullback: Health-Care Shares

"As sentiment and the stock market increasingly look bearish, look for the recent outperformance in health care to continue," The Wall Street Journal reports. Health-care firms were "hardly a leader" during the "initial run of stocks following the March lows," but they also "fared much better during the market"s plummet. Last week, "health care was the one exception to a sliding market." Katie Stockton, chief market technician for MKM Partners, "says it is likely most of the health-care sector will outperform and not just large pharmaceutical companies" (Rogow, 6/23). Business Week reports that health care"s reputation as a "defensive" stock market sector that "resists recession" is now "being put to the test. The result? More than a year into a nasty recession, health-care profits have barely budged. In the current scheme of things, that"s a pretty good performance." But deals and proposals for health care reform "could create major and unpredictable shifts in the way health care is paid for in the U.S," and many health care firms are "unquestionably feeling the effects of the economic slowdown." Walgreen, for example, "disappointed investors with lower-than expected earnings" as "higher costs ate into profit margins." Sales of prescriptions were up, "but sales results were weighed down by slow consumer spending in the rest of the store," and "the recession has only heightened competition between Walgreen and its rivals." And "even as it deals with the bad economy and a tough competitive landscape, Walgreen - like other health-care-related stocks - could be hugely affected by Obama"s health-care reform plans. The cost-cutting deal between Obama and drug companies is one sign of how much the sector"s profitability could be squeezed" (Steverman, 6/22). Meanwhile, Dow Jones Newswires reports on a pharmaceutical analyst who "thought he knew all about the U.S. health-care system" until he was diagnosed with Hodgkin"s disease. "Now, with the cancer in remission, [Robert] Hazlett brings a deeper appreciation of patients" needs to his job." Hazlett says his illness has made him more sensitive to patient"s perspectives and has also "left him conflicted about the link between profits and life-saving drugs" (Loftus, 6/22). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):